SBRT vs Conventional Radiation + Chemotherapy for Pancreatic Cancer
Trial Summary
Do I need to stop my current medications for this trial?
The trial protocol does not specify if you need to stop taking your current medications, but it does mention that patients taking nonprotocol-specified chemotherapy agents or immune modulating agents for other conditions cannot participate. It's best to discuss your current medications with the trial's principal investigator.
What data supports the effectiveness of the treatment Preoperative Fractionated Radiation Therapy and Chemotherapy, Stereotactic Body Radiation Therapy, Stereotactic Ablative Radiotherapy (SABR), CyberKnife for pancreatic cancer?
Research shows that stereotactic ablative radiation therapy (SABR) and stereotactic body radiation therapy (SBRT) using CyberKnife can be effective for treating locally advanced and metastatic pancreatic cancer, especially after initial chemotherapy. These treatments are known for their precision and shorter treatment times, which can be beneficial for patients.12345
Is SBRT using CyberKnife safe for pancreatic cancer patients?
Studies have evaluated the safety of Stereotactic Body Radiation Therapy (SBRT) using CyberKnife for pancreatic cancer, showing it is generally safe for patients, including those with advanced or recurrent conditions. Safety has also been assessed in other cancers, like liver cancer, indicating it is a well-tolerated treatment option.24567
How is the SBRT treatment different from other treatments for pancreatic cancer?
SBRT (Stereotactic Body Radiation Therapy) is unique because it delivers high doses of radiation in a shorter time compared to conventional radiation, which can minimize disruption to chemotherapy schedules and potentially improve surgical outcomes and survival rates for pancreatic cancer patients.89101112
What is the purpose of this trial?
Patients are randomized into two arms. Arm A patients will receive Stereotactic Body Radiation Therapy (SBRT) and Arm B patients with receive conventional concurrent chemotherapy and radiation therapy.
Research Team
William Hall, MD
Principal Investigator
Medical College of Wisconsin
Eligibility Criteria
Adults over 18 with a specific type of pancreatic cancer (type A adenocarcinoma) that is resectable, borderline resectable, or locally advanced. They should have had two months of chemotherapy without disease spread and be able to swallow pills. Pregnant women and those not using contraception are excluded.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Induction Chemotherapy
Participants receive a minimum of one cycle of induction chemotherapy before randomization
Treatment
Participants are randomized to receive either Stereotactic Body Radiation Therapy (SBRT) or conventional concurrent chemotherapy and radiation therapy
Surgical Resection
Subjects undergo surgical resection within three to eight weeks following treatment
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Preoperative Fractionated Radiation Therapy and Chemotherapy
- Stereotactic Body Radiation Therapy
Find a Clinic Near You
Who Is Running the Clinical Trial?
Medical College of Wisconsin
Lead Sponsor